- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
GSK’s corporate Twitter shared Zejula trial/regulatory updates in a Q2 results thread. PMCPA said the tweet was accessible to the public and…
A GP complained about a rep’s non-headed letter seeking an appointment but making efficacy/price claims. PMCPA ruled it was promotional, uncertified and…
A BMJ-hosted promotional ‘tile’ for Viridal showed the brand name without the non-proprietary name and lacked certification. UCB said an agency published…
Galderma’s GP letter promoting Silkis as an alternative to Dovonex used broad claims on steroid comparability, cosmetic acceptability and “cost effective”. Panel…
MSD published an incorrect Disclosure UK entry showing a health professional received congress support. Error arose from selecting the wrong person with…
A PCT medicines management head complained about a reply card offering a branded memory stick if they booked a rep visit. Panel…
Anonymous complaint about Serono rep call-rate targets. A typo in an “Activity Standards” document implied 3 calls per cycle (3 cycles/year), potentially…
Intercompany complaint about information on a website. The PMCPA found the matter outwith the scope of the Code, so no breach was…
Anonymous GP complaint about a product standardization programme in Northern Ireland. Case did not go before the Panel; programme already withdrawn. No…
A health professional alleged promotion of a prescription medicine to the public by Bayer. The PMCPA recorded no breach and found the…
A LinkedIn launch post and linked press release for Xonvea were found to include product claims and be disseminated to the public,…
MSD gave an inter-company undertaking to withdraw materials wrongly showing alogliptin with a black triangle, but an outdated Januvia leavepiece was still…
Otsuka voluntarily admitted errors/omissions in prescribing information across four medicines. PMCPA found breaches focused on Samsca PI being inconsistent with the SPC,…
GSK’s Relvar Ellipta Pulse ad was challenged on generic name placement and a “25% more patients improve asthma control” claim. The PMCPA…
After inter-company dialogue, Ipsen’s “Dysport – a toxin with a long-lasting effect” messaging was found to imply an unsubstantiated duration advantage. Appeal…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.